We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App

Powerful Brain Imaging Allows Researchers to Pinpoint Tissue Damage Following COVID-19 Illness

By HospiMedica International staff writers
Posted on 26 Mar 2021
Print article
Image: Three 7T MRI scans demonstrating the high level of contrast and resolution that allows researchers to pinpoint tissue damage following COVID-19 illness (Photo courtesy of Rob Bartha / Robarts Research Institute)
Image: Three 7T MRI scans demonstrating the high level of contrast and resolution that allows researchers to pinpoint tissue damage following COVID-19 illness (Photo courtesy of Rob Bartha / Robarts Research Institute)
A multidisciplinary team of more than a dozen scientists and clinicians are combining their expertise and will use powerful brain-imaging to better understand the effects of COVID-19 on the brain.

Scientists and clinicians at Robarts Research Institute and the Schulich School of Medicine & Dentistry at Western University (London, ON, Canada) are capitalizing on interdisciplinary research strengths, including experts in brain imaging, cognitive neurology and infectious disease. Since the virus was identified in the population just over a year ago, researchers and physicians have been observing neurological and cognitive symptoms sometimes associated with the illness. Physicians have seen a whole range of such symptoms, including memory loss or confusion, severe headaches and loss of the sense of smell. In rare, severe cases, hospitalized patients develop stroke.

While they have been able to observe these varied symptoms, scientists have not yet got to the bottom of what’s happening in the brain to cause them. Since some people with COVID-19 develop blood clots and changes in blood vessels, the research team believes the neurological symptoms could be caused by the virus triggering tiny vessels to bleed in the brain — what’s known clinically as microbleeds. Some of these tiny brain injuries are so small that they aren’t visible with clinical brain imaging done in hospitals.

However, an ultra-high-field MRI scanner at Robarts’ Centre for Functional and Metabolic Mapping is more than twice as powerful as a conventional MRI and can scan the brain in extremely high resolution. Researchers at Robarts have developed specialized techniques to use the 7-Tesla MRI to observe even the tiniest of microbleeds. They can also pick up very subtle changes to white matter that can show where the brain has been damaged, and track changes in acidity in the brain that can indicate where it’s been deprived of oxygen. The team is hoping to recruit 60 patients who have experienced neurological symptoms from COVID-19. The researchers will do cognitive testing to observe changes in functioning after the illness and also run a full gamut of MRI scans. The hope is to determine exactly what is happening in the brains of COVID-19 patients and gain insight into what the long-term effects might be.

“What we are doing here is very comprehensive and unique,” said Robert Bartha, PhD, acting director, Strategy and Scientific Integration at Robarts, who is leading the imaging side of the study. “We are bringing together a number of very advanced measures that we’ve developed in other studies to look at multiple sclerosis, Alzheimer’s disease and epilepsy in order to try to get a fulsome picture of what’s happening neurologically in COVID-19.”

“One of the really interesting questions that we are hoping to answer is the effect of COVID-19 on developing other diseases later life,” added Bartha. “Any time you have a condition that causes insult to the brain, it brings in the question about whether this might accelerate the processes that leads to neurodegenerative diseases like Alzheimer’s or dementia.”

Related Links:
Western University

Print article



view channel
Image: Respicardia’s remedē System (Photo courtesy of Respicardia, Inc.)

Zoll Medical Acquires CSA Systems Manufacturer Respicardia

ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.